News

The International Myeloma Foundation (IMF), the largest organization focusing specifically on multiple myeloma (MM), is now alerting that a reportedly flawed document evaluating…

Positive data for the Phase 1 trial of PharmaMar’s plitidepsin combined with bortezomib and dexamethasone for the treatment of relapsed and/or refractory multiple…

Amgen announced it will present new data on its cancer portfolio at the 21st Congress of the European Hematology (EHA) Association taking place next month in Copenhagen. The…

Spain-based PharmaMar announced the company will present data from several clinical studies of three of its anti-tumoral compounds of marine origin — plitidepsin, Yondelis (trabectedin),…

Results from an ongoing clinical trial supports the use of upfront autologous stem cell transplantation (ASCT) to treat multiple myeloma patients age 65 or younger.

Genmab has announced positive results from its Phase 3 POLLUX study investigating the efficacy of daratumumab, in combination with lenalidomide and dexamethasone, to treat patients with…

Ajai Chari, MD, director of clinical research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai in New York, and Navneet Majhail,…

Leisure-time physical activity is associated with a lower risk for many types of cancer, including a 17 percent lower risk for myeloma. These key findings were independent of…

Newton, Massachusetts-based Karyopharm Therapeutics has published the results from its Phase 1 trial of selinexor (KPT-330) in patients with advanced solid tumors in the…

Three organizations — CURE Media Group, Multiple Myeloma Research Foundation (MMRF) and Takeda Oncology — joined together in the Moving Mountains for Multiple…